Clinical trial
Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in…
NCT00460096 · Kamada, Ltd., Industry · Completed
Key facts
| NCT number | NCT00460096 |
|---|---|
| Title | Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency |
| Official title | Randomized Double-Blind Comparison of an Alpha-1 Proteinase Inhibitor (Kamada API) With a Currently Marketed API Product in Individuals With Alpha-1 Antitrypsin Deficiency |
| Acronym | Kamada API |
| Lead sponsor | Kamada, Ltd., Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Alpha 1-Antitrypsin Deficiency |
| Intervention type | Drug |
| Interventions | Kamada-API |
| Enrollment | 50 |
| Start date | Mar 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Apr 13, 2007 |
| Last update posted | Oct 17, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: